Mind Matters Weekly: Exploring Breakthroughs in Modern Mental Health

In the late 1950s, the actor Cary Grant publicly credited his LSD therapy with helping him, quote, “get close to happiness.” Last week we talked about the paradigm shifts reshaping mental health, and this feels like a ghost from a past we almost forgot we had. It's a reminder that the conversation around psychedelic-assisted therapy isn't new... it's just been on pause for about sixty years. And this week, the volume on that conversation got turned way up. The White House issued an executive order on April 18th to accelerate FDA review of psychedelic drugs for serious mental illness.

This comes right after Compass Pathways announced two positive phase three trials for its synthetic psilocybin, COMP360, which the FDA has now fast-tracked for treatment-resistant depression. It’s not just talk; the Department of Veterans Affairs has also committed one-point-five million dollars to study these therapies for veterans. But here’s the tension: this wave of support is happening just two years after a 2024 FDA advisory panel voted overwhelmingly that MDMA-assisted therapy for PTSD was not proven effective and that its risks outweighed its benefits. So what is going on?

Let’s get very clear about what we’re talking about. Psychedelic-assisted therapy, or PAT, is not taking mushrooms with your friends and hoping for the best. It's a structured, clinical process. Think of it like a minor medical procedure for the mind. You’re in a safe, comfortable room with one or two trained therapists. You might have eye shades, headphones with a specific music playlist. The session itself can last six to eight hours. And it’s bracketed by weeks of traditional psychotherapy—sessions before to prepare you, and sessions after to help you integrate what you experienced.

The drug isn't the therapy; the drug is the key that unlocks a door so the therapy can happen. So where have we seen this before? Well, the 1950s and 60s were full of this. Researchers like Humphry Osmond were giving mescaline to Aldous Huxley and seeing profound results for things like alcoholism. But then the culture wars hit, and the research slammed to a halt. The pattern then was: scientific promise followed by social panic. The pattern now is… more complicated. We have the scientific promise making a comeback, but this time it’s running into the wall of modern regulatory standards.

And that’s where the analogy breaks down. The FDA panel that voted against MDMA in 2024 wasn’t having a moral panic. They were asking tough, necessary questions about the data. How can you have a truly "blind" study when patients obviously know if they've received MDMA? How do you account for the intense therapeutic support as a variable? These are fair questions. The problem is that the tool—the psychedelic experience—doesn't fit neatly into the boxes our drug trials were designed to measure. We're trying to measure a hurricane with a rain gauge. So this week’s news—the White House order, the COMP360 fast-track—it isn't about ignoring those questions.

It’s a signal that the institutions themselves recognize the tools might be broken. They’re saying, okay, this is promising enough that we need to figure out a new way to measure it, a new pathway to approve it if it works. It’s a move from "does this fit our system?" to "how do we adapt our system for this?" This whole episode is a profound test for the field of mental health. It’s forcing us to confront not just a new class of compounds, but the very limits of our models for what healing looks like and how we prove it.